Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2019 May 24;11(5):e4749.
doi: 10.7759/cureus.4749.

Congenital Adrenal Hyperplasia Presenting as Pulseless Ventricular Tachycardia in a Neonate

Affiliations
Case Reports

Congenital Adrenal Hyperplasia Presenting as Pulseless Ventricular Tachycardia in a Neonate

Nida Manzoor et al. Cureus. .

Abstract

Congenital adrenal hyperplasia (CAH) comprises a group of autosomal recessive inherited disorders that arise due to defects in one of the enzymes of steroidogenesis pathway in the adrenal glands. Ninety-five percent of the cases occur due to deficiency in 21-hydroxylase (21-OH). Clinically, CAH due to 21-OH deficiency presents in two distinct forms, classic CAH and non-classic CAH. Females with classical forms present with genial ambiguity while the presentation in males is more subtle with severe electrolyte disturbances being the initial manifestation in many cases. Arrhythmias are a rare manifestation of CAH. We report the case of an 18-day-old male child who presented with pulseless ventricular tachycardia and was later diagnosed with congenital adrenal hyperplasia based on the laboratory findings of elevated 17-hydroxyprogesterone (17-OHP) levels. Our case reveals that fatal arrhythmias such as a pulseless ventricular tachycardia can be the primary manifestation of the adrenal insufficiency of CAH even in the absence of any physical findings and hence clinicians should always maintain a strong suspicion for CAH in any child presenting with unexplained arrhythmia. Furthermore, this case also highlights the need for CAH screening in neonates so that the appropriate hormone replacement can be initiated before the development of life-threatening adrenal crisis.

Keywords: congenital adrenal hyperplasia; pulseless ventricular tachycardia.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. Electrocardiogram tracing showing ventricular tachycardia with absent P waves and broad QRS complexes

Similar articles

References

    1. Future directions in the study and management of congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Merke DP, Bornstein SR, Avila NA, Chrousos GP. Ann Intern Med. 2002;136:320–334. - PubMed
    1. Recent advances in diagnosis, treatment, and outcome of congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Riepe FG, Sippell WG. Rev Endocr Metab Disord. 2007;8:349–363. - PubMed
    1. Congenital adrenal hyperplasia. Speiser PW, White PC. N Engl J Med. 2003;349:776–788. - PubMed
    1. Congenital adrenal hyperplasia. Merke DP, Bornstein SR. Lancet. 2005;365:2125–2136. - PubMed
    1. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline. Speiser PW, Azziz R, Baskin LS, et al. J Clin Endocrinol Metab. 2010;95:4133–4160. - PMC - PubMed

Publication types

LinkOut - more resources